View Author
patient group study treatment donor survival leukemia remission cycle myeloid leukemia cytogenetic university chemotherapy result outcome square meter induction cytarabine therapy response relapse blood myeloid table adult dectin aspergillu value trial effect lymphoblastic leukemia daunorubicin disease erasmus university square analysis meter number allo-sct -17 transplantation death fumigatu abnormality erasmu sibling high-dose event-free survival center cell transplantation event-free hospital nejm.org escalated-dose group no-donor group donor group netherland factor ratio consolidation aspergillosi performance status control month y 238x polymorphism donor availability conventional-dose group lymphoblastic classi fied no-donor hovon 60 years il -17 receptor allogeneic e ng l signi sibling donor infection status
9 Most Recent Publications
|
Early Serum Galactomannan Trend as a Predictor of Outcome of
Invasive Aspergillosis
(Article)
Chai, L.Y.A. Kullberg, B.J. Herbrecht, R. Johnson, E.M. Teerenstra, S. Khin, L.W. Maertens, J. Lortholary, O. Donnelly, P.J. Schlamm, H.T. Troke, P.F. |
2012-07-01
|
|
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
(Article)
Rijneveld, A.W. Holt, B. van der Wijermans, P. Wittebol, S. Spoelstra, F.M. Dekker, A.W. Ossenkoppele, G.J. Willemze, R. Cornelissen, J.J. Daenen, S.M.G.J. Biemond, B.J. de Weerdt, O. Muus, P. Maertens, J. Mattijssen, V. Demuynck, H. Legdeur, M.C.J.C. |
2011-06-07
|
|
Cytarabine dose for acute myeloid leukemia
(Article)
Löwenberg, B. Pabst, T. Greef, G.E. de Verdonck, L.F. Schaafsma, M.R. Gregor, M. Theobald, M. Schanz, U. Maertens, J. Ossenkoppele, G.J. Vellenga, E. Putten, W. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Biemond, B.J. Gratwohl, A. |
2011-03-17
|
|
The Y238X stop codon polymorphism in the human b-glucan receptor dectin-1 and susceptibility to invasive aspergillosis
(Article)
Chai, L.Y.A. Boer, M.G.J. de Donnelly, P.J. Kullberg, B.J. Maertens, J. Netea, M.G. Velden, W.J.F.M. van der Plantinga, T.S. Spriel, A.B. van Jacobs, C. Halkes, C.J.M. Vonk, A.G. Blijlevens, N.M. Dissel, J.T. van |
2011-03-01
|
|
Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity
(Article)
Chai, L.Y.A. Veerdonk, F. van de Kullberg, B.J. Netea, M.G. Marijnissen, R.J. Cheng, S.C. Khoo, A.L. Hectors, M. Lagrou, K. Vonk, A.G. Maertens, J. Joosten, L.A.B. |
2010-05-01
|
|
Gemtuzumab ozogamicin as postremission treatment inAMLat 60 years of age or more: results of a multicenter phase 3 study
(Article)
Löwenberg, B. Beck, J.A. Biemond, B.J. Vellenga, E. Breems, D.A. Muijnck, H. de Schaafsma, R. Verhoef, G. Döhner, H. Gratwohl, A. Pabst, T. Ossenkoppele, G.J. Graux, C. Maertens, J. Putten, W.L.J. van Schouten, H.C. Verdonck, L.F. Ferrant, A. Sonneveld, P. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2010-04-01
|
|
High-dose daunorubicin in older patients with acute myeloid leukemia
(Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2009-09-24
|
|
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison
(Article)
Cornelissen, J.J. Holt, B. van der Wijermans, P.W. Biesma, D.H. Wittebol, S. Voogt, P.J. Baars, J.W. Zachée, P. Verdonck, L.F. Löwenberg, B. Dekker, A.W. Verhoef, G.E.G. Veer, M.B. van 't Oers, M.H.J. van Ossenkoppele, G.J. Sonneveld, P. Maertens, J. Marwijk Kooy, M. van Schaafsma, M.R. |
2009-02-05
|
|
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?
(Article)
Cornelissen, J.J. Putten, W.L.J. van Lelie, H. van der Fey, M. Ferrant, A. Maertens, J. Gratwohl, A. Löwenberg, B. Verdonck, L.F. Theobald, M. Jacky, E. Daenen, S.M.G.J. Marwijk Kooy, M. van Wijermans, P.W. Schouten, H. Huijgens, P.C. |
2007-05-01
|
